Stock CPMD CANNAPHARMARX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

CannaPharmaRX, Inc. Stock

Equities

CPMD

US13765D1090

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 13:46:00 2024-04-17 EDT 		5-day change 1st Jan Change
0.01 USD -31.03% Intraday chart for CannaPharmaRX, Inc. 0.00% +488.24%
03-14 CannaPharmaRX, Inc. Receives First Purchase Order and Begins Shipment of Product CI
03-05 CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with Ican to Create Distribution Network in the Latin Americas CI

Financials

Sales 2021 - Sales 2022 - Capitalization 2.57M 3.51M
Net income 2021 -8M -10.94M Net income 2022 -8M -10.94M EV / Sales 2021 -
Net Debt 2021 8.99M 12.29M Net Debt 2022 14.52M 19.85M EV / Sales 2022 -
P/E ratio 2021
-0.11 x
P/E ratio 2022
-0.25 x
Employees 6
Yield 2021 *
-
Yield 2022
-
Free-Float 97.33%
More Fundamentals * Assessed data

Chart CannaPharmaRX, Inc.

Dynamic Chart

Latest news about CannaPharmaRX, Inc.

CannaPharmaRX, Inc. Receives First Purchase Order and Begins Shipment of Product CI
CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with Ican to Create Distribution Network in the Latin Americas CI
CannaPharmaRx, Inc Enters into Strategic Supply Agreement with Cantek Holdings CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
CannaPharmaRX, Inc. Announces Executive Changes CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
CannaPharmaRx Expands Board of Directors CI
CannaPharmaRX, Inc. Announces CEO Changes CI
CannaPharmaRX, Inc. Signs Supply Agreement with Y.S.A Holdings for Up to $15 Million Annually of Commercial Cannabis CI
CannaPharmaRX, Inc. completed the acquisition of LTB Management LLC. CI
CannaPharmaRX, Inc. agreed to acquire LTB Management LLC. CI
CannaPharmaRx Receives Canada Revenue Agency License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected CI
CannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 Million CI
More news

Press releases CannaPharmaRX, Inc.

CANNAPHARMARX, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) AQ
Canadian Cannabis; Down but Far from Out - Growth for 2023 and Beyond NE
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Revenue Over $30 Million AQ
CANNAPHARMARX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
CANNAPHARMARX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
More press releases

Quotes and Performance

1 day-31.03%
Current month-32.43%
1 month-39.39%
3 months+614.29%
6 months+42.86%
Current year+488.24%
More quotes

Highs and lows

1 month
0.01
Extreme 0.01
0.02
Current year
0.00
Extreme 0.0007
0.03
1 year
0.00
Extreme 0
0.03
3 years
0.00
Extreme 0
0.25
5 years
0.00
Extreme 0
2.99
10 years
0.00
Extreme 0
4.98
More quotes

Managers and Directors - CannaPharmaRX, Inc.

Managers TitleAgeSince
Dean Medwid CEO
 Chief Executive Officer - 23-05-31
Dominick Colvin CEO
 Chief Executive Officer 55 16-12-31
Oliver Foeste DFI
 Director of Finance/CFO 48 23-10-12
Members of the board TitleAgeSince
Rick Orman CHM
 Chairman 74 19-04-22
Dominick Colvin CEO
 Chief Executive Officer 55 16-12-31
Anthony Panek BRD
 Director/Board Member 39 23-08-24
More insiders

Quotes

Date Price Change Volume

Delayed Quote OTC Markets, April 17, 2024 at 01:46 pm

More quotes

Company Profile

CannaPharmaRx, Inc. is focused on the acquisition and development of state-of-the-art cannabis growing facilities in Canada. The Company is engaged in producing customizable medical cannabis and craft products. Its business strategy is to produce a high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. The Company is focused on operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis. The Company also offers a range of services to assist with cannabis inventory management.
Sector
Pharmaceuticals
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CANNAPHARMARX, INC. Stock CannaPharmaRX, Inc.
+488.24% 6.54M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CPMD Stock